The safety and efficacy of many stem cell treatments remain unproven by the FDA, yet state laws promote access and use of these unchecked and potentially harmful treatments. Fellow Kirstin R.W. Matthews summarizes her recent publication in a new commentary — outlining public health consequences of these state laws and calling for scientific societies’ advocacy in state policymaking.
The number of anti-vaccine bills filed in Texas has risen, yet many Texans support vaccine policy. Fellow Kirstin R.W. Matthews and nonresident scholar Rekha Lakshmanan examine the stakes of legislative engagement in public health initiatives and provide a call to action for Texans to embrace public health as an act of freedom.
Will OPEC+ begin to reverse large production cuts at its June 1 meeting? In large part, it will depend on whose oil market outlook is closest to the mark, writes Mark Finley, fellow in energy and global oil. He examines several forecasts and outlines the issues in a new commentary.
Mark Finley explains the cost-benefit analysis behind the Saudi government's recent move to pause plans to increase spare oil production capacity — and why spare capacity still equates to power in the oil market.
For research involving human embryos and other controversial subjects, science journals should require ethics statements from researchers detailing research oversight, what embryos were used, how many and for how long. This will help increase transparency and improve communication with the public, writes Science and Technology Policy Fellow Kirstin R.W. Matthews.
When the OPEC+ group met last week and agreed to extend production cuts through the first quarter of 2024, the market was unimpressed. Fellow in Energy and Global Oil, Mark Finley, outlines the meeting’s outcomes and discusses why the recent agreement “could augur a year of difficult meetings ahead” in a new commentary.